Lakewood-Amedex Biotherapeutics, Inc. (LABT) shares declined 20.00 percent to $1.2000, down $0.3000 on Monday, even after the clinical-stage biotechnology company reported positive manufacturing and stability data for its lead antimicrobial candidate, Nu-3.
The stock is currently trading at $1.2000, compared with a previous close of $1.5000 on the Nasdaq. It opened at $1.3600 and traded between $1.0700 and $1.4700 during the session, with volume reaching 34.73 million shares, well above the average daily volume of 3.31 million shares.
The company said Nu-3, a topical treatment being developed for mildly infected diabetic foot ulcers, demonstrated favorable manufacturing progress and long-term stability. Drug substance remained stable for at least five years, while the gel formulation was stable for at least two years and showed undetectable bioburden levels without requiring additional preservatives.
Lakewood-Amedex shares have traded between $1.0700 and $9.8200 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.